FIG.1A

TO oo CLINIC

DOCTOR

COLLECTION DATE XX (YEAR) XX (MONTH) XX (DAY)
RECEPTION DATE XX (YEAR) XX (MONTH) XX (DAY)
REPORTING DATE XX (YEAR) XX (MONTH) XX (DAY)
DEPARTMENT
OUTPATIENT/HOSPITALIZATION

MEDICAL CHART No.
NAME OF PATIENT
AGE
SEX

ITEM NAME		RESULT		REFERENCE VALUE	
NUMBER OF WHITE BLOOD CELL		WBC	××	3,500～9,700/μℓ	
NUMBER OF RED BLOOD CELL		RBC	××	M 438～577 F 376～518 ×10⁴/μℓ	
HEMOGLOBIN CONTENT		Hb	××	M 13.6～18.3 F 11.2～15.2 g/dℓ	
HEMATOCRIT		Ht	××	M 40.4～51.9 F 34.3～45.2 %	
MCV		MCV	××	M 83～101 F 80～101 fl	
MCH		MCH	××	M 28.2～34.7 F 26.2～34.3 pg	
MCHC		MCHC	××	M 31.8～36.4 F 31.3～36.1 %	
NUMBER OF PLATELET		PLATELET	××	14.0～37.9 ×10⁴/μℓ	
RETICULOCYTE		RETICULAR		0.1～2.6 %	
WHITE BLOOD CELL IMAGE	Baso	B	××	0～2 %	
	Eosino	E	××	0～7 %	
	Neutro	N	××	42～74 %	
	Stab	St		0～19 %	
	Seg	Seg		27～72 %	
	Lympho	L	××	18～50 %	
	Mono	Mon	××	1～8 %	
	OTHER 1		××		
	OTHER 2		××		
	EBL	EBL	××		
RED BLOOD CELL MORPHOLOGY	DIFFERENCE IN SIZE	LARGE AND SMALL		(—)	
	MALFORMATION	MALFORMATION		(—)	
	POLYCHROMASIA	POLYCHROMATOSIS		(—)	
	NUCLEATED	NUCLEATED		(—)	
(SPECIFIC GRAVITY OF WHOLE BLOOD)		GB		M 1.055～1.093 F 1.052～1.090	
COMPLETION OF TEST		TOTAL XX SCORE		XX (YEAR) XX (MONTH) XX (DAY)	

FIG.1B

TO oo CLINIC

DOCTOR

COLLECTION DATE XX (YEAR) XX (MONTH) XX (DAY)
RECEPTION DATE XX (YEAR) XX (MONTH) XX (DAY)
REPORTING DATE XX (YEAR) XX (MONTH) XX (DAY)
DEPARTMENT
OUTPATIENT/HOSPITALIZATION

MEDICAL CHART No.
NAME OF PATIENT
AGE
SEX

ITEM NAME	RESULT	REFERENCE VALUE	SCORE
#CD3	××	58.6 ～ 89.0 %	××
#Two-color			
# CD4+ CD8+	××	0.2 ～ 0.4 %	
# CD4+ CD8−	××	30.2 ～ 40.2 %	
# CD4− CD8+	××	21.5 ～ 30.5 %	
# CD4− CD8−	××	33.4 ～ 43.6 %	
#Two-color			
# CD16+ CD56+	××	%	××
# CD16+ CD56−	××	%	
# CD16− CD56+	××	%	
# CD16− CD56−	××	%	

FIG.2



* ENHANCEMENT OF Th1 IMMUNITY = SYSTEMIC KILLING POWER OF CANCER
* SOLE KILLING POWER

- Th1 CELLULAR IMMUNITY = NK + CD8 (KILLER T CELL)
- Th2 HUMORAL IMMUNITY = NKT + B CELL
- Th17 (GASTROINTESTINAL TRACT)
- Treg = IMMUNOSUPPRESSION (REGULATORY T-CELL)

FIG.3

RENAL CANCER	(TEN MILLION)
WHITE BLOOD CELL	1904
GRANULOCYTE	1129
MONOCYTE	99
LYMPHOCYTE	676
T CELL	477
NON-T CELL	199
CD_4	209
CD_8	166
NK CELL	35
NKT CELL	6.7
B CELL	161
GRANULOCYTE	1129
MONOCYTE	99
CD_4	209
CD_8	166
NK CELL	35
NKT CELL	6.7
B CELL	161

(A)



(B)



(C)



FIG.4A

CASE OF IMMUNOSUPPRESSION BY ANTICANCER AGENT

END-STAGE ESOPHAGEAL CANCER AGE 56 MALE
EXAMPLE OF DEATH DURING MEDICAL TREATMENT WITH ANTICANCER AGENT
(CLINICAL DATA AT 2 DAYS BEFORE DEATH)



EXTREMELY ABNORMAL DECREASE
IN NUMBER OF CD4 LYMPHOCYTE
WHICH IS CENTER OF IMMUNE SYSTEM

・GRANULOCYTE : MONOCYTE : LYMPHOCYTE
= 95↑ : 3 : 2↓%

・CD4≈46/μ1<100/μ1
(STRONG CRISIS STATE OF IMMUNITY)

FIG.4B

CASE OF IMMUNOSUPPRESSION BY ANTICANCER AGENT

HEALTHY SUBJECT AGE 94 FEMALE



GRANULOCYTE : MONOCYTE : LYMPHOCYTE = 59 : 7 : 34%

・NORMAL SUBJECT (IDEAL RATIO)
・GRANULOCYTE : MONOCYTE : LYMPHOCYTE
= 60 : 5 : 35%

・LYMPHOCYTE WHICH IS CENTER OF IMMUNE SYSTEM = HELPER T CELL
CD_4=741/μ1<600/μ1
(SHOWING HIGH NUMBER OF NORMAL IMMUNITY)

FIG.4C

CASE OF IMMUNOSUPPRESSION BY ANTICANCER AGENT

COLON CANCER AGE 79 FEMALE
(RECEIVED TREATMENT WITH ANTICANCER AGENT UNTIL ONE YEAR AGO)



IMMUNOCOMPROMISED STATE CONTINUED
DESPITE WITHDRAWAL OF ANTICANCER AGENT
ONE YEAR AGO AND APPROXIMATELY SEMIPERMANENT
IMMUNOSUPPRESSION WASSHOWN

・GRANULOCYTE : MONOCYTE : LYMPHOCYTE
= 87↑ : 4 : 9↓%

・CD4≈240/μ1<400/μ1
(IMMUNE DEPRESSION)

FIG.5

CHRONIC RHEUMATOID ARTHRITIS AGE 82 FEMALE	(TEN MILLION)
NK CELL	64
CD8	33
CD4	87
NKT CELL	5
B CELL	146
MONOCYTE	111
GRANULOCYTE	1665
T CELL	203
Th1/Lym %	29
Th2/Lym %	71
B CELL /Lym %	44
B/CD4>1	
Eosino.(%) (EOSINOPHIL)	0.2

(A)



(B)



ATOPIC DERMATITIS AGE 34 MALE	(TEN MILLION)
NK CELL	38
CD8	199
CD4	193
NKT CELL	4.8
B CELL	288
MONOCYTE	121
GRANULOCYTE	1578
T CELL	600
Th1/Lym %	32
Th2/Lym %	68
B CELL /Lym %	40
B/CD4>1	
Eosino.(%) (EOSINOPHIL)	6.1

B CELL>CD4 T CELL NUMBER
SHOWING Th2 HUMORAL IMMUNITY DOMINANCE
(DEVIATION TO Th2 HUMORAL IMMUNITY)

FIG.6A


10
11
12
13
14
19
CPU
RAM
ROM
STORAGE UNIT
COMMUNICATION I/F
MONITOR
OUTPUT UNIT
INPUT UNIT
15
16
17
18

FIG.6B


10
18
20
16
INPUT UNIT
CALCULATION UNIT
MONITOR
STORAGE UNIT
OUTPUT UNIT
14
17